M&D Specialty Distribution Adds More than 50 Specialty Drugs to Expansive Portfolio
Specialty drugs are becoming increasingly vital for treating complex and chronic conditions. Morris & Dickson Specialty Distribution (MDSD) is at the forefront of this trend, having recently expanded its specialty distribution portfolio by adding over 50 new specialty drugs through an agreement with pharmaceutical leader, Johnson & Johnson. This includes notable additions like Darzalex® and Stelara®, which are now available in stock, enhancing the company’s ability to support a wide range of therapeutic areas, from oncology to rare diseases. By partnering with MDSD, healthcare providers can ensure they have access to the latest and most advanced treatments.
Expanding the specialty portfolio: What’s new
Also among the new additions are several notable drugs from Johnson & Johnson, including Remicade®, Simponi®, Tremfya®, Zytiga®, Invega®, Monovisc®, Orthovisc®, Procrit®, Risperdal®, and Xarelto®. These drugs cover a broad spectrum of therapeutic areas, including oncology, rheumatology, and rare diseases. These additions, along with the comprehensive range of more than 200 other specialty products, ensure that MDSD can support a wide array of patient care needs.
Why specialty drugs matter in today’s market
As the healthcare landscape continues to evolve, specialty drugs have emerged as a critical component in the treatment of complex and chronic conditions. The precision and effectiveness of specialty drugs make them indispensable for improving patient outcomes and quality of life. For instance, in oncology, specialty drugs like Darzalex have revolutionized the treatment of multiple myeloma, offering patients new hope and extended lifespans.
This trend underscores the importance of healthcare providers partnering with reliable specialty distribution providers. These medications often come with high costs and stringent handling requirements, including temperature control, specialized packaging, and strict regulatory compliance. MDSD is equipped to manage these challenges, ensuring that specialty drugs are delivered safely and efficiently to healthcare providers and, ultimately, to patients.
Backed by 180-plus years of distribution and cold chain expertise of Morris & Dickson, MDSD excels in handling specialty medications with unique storage requirements such as refrigerated, freezer, and ultra-cold storage down to -80°C.
MDSD also offers a suite of comprehensive support services that streamline both the healthcare providers’ and the pharmaceutical manufacturers’ operations. These services include advanced logistics, efficient inventory management and stringent regulatory compliance and group purchasing services for specialty clinics and infusion centers.
The company’s strategic alliances with leading pharmaceutical manufacturers and biotech companies have been instrumental in securing a diverse and robust portfolio of specialty drugs that include newly approved drugs to market, exclusive drugs where there are no other treatments, plasma-derived medicines and biosimilars.
This level of complex support from MDSD ensures healthcare providers have access to advanced treatments, and that these medications are delivered safely and on time, maintaining the integrity of the treatments and the trust of the providers and patients alike.
To learn more, contact M&D Specialty Distribution at (800) 388-3833.